Join
Live feed
·
PRReleasevia Quantisnow
Bristol-Myers Squibb Company logo

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

ByQuantisnow·Wall Street's wire, on your screen.
BMY· Bristol-Myers Squibb Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMY (Bristol-Myers Squibb Company) and more on Quantisnow.